We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Tool to Aid Drug Development

By Biotechdaily staff writers
Posted on 29 Mar 2005
A new mathematical algorithm can predict the precise effects a given compound will have on a cell's molecular components, aiding the efforts of researchers to design compounds that will act only on desired gene and protein targets and elicit responses free of unwanted side effects.

Until now, there have been few ways to predict the effects of optimal drug design. The molecular targets of many drug targets are unknown and are often difficult to tease out from among the thousands of gene products found in a typical organism. This is why the drug-designing process is neither precise nor efficient .

A team of biochemical engineers and chemists at Boston University (MA, USA) has tried to make the process more efficient and precise. The team used a combination of computational and experimental methods to build and verify their tool, first using a reverse-engineering approach to decipher the multitude of regulatory networks operating among genes in a simple organism, then testing the ability of the resulting network models to predict gene and pathway targets for a variety of drug treatments. They used this tool to predict the molecular targets of a potential new anticancer compound (PTSB) shown in studies to inhibit growth in the test organism (baker's yeast) as well as in human small lung carcinoma cells.

Their algorithm predicted that PTSB acted on thioredoxin and thioredoxin reductase, findings that not only validated the tool's capability but also paved the way to investigations of a potentially new class of therapeutic compounds. The research team was led by Tim Gardner, an assistant professor in the College of Engineering's department of biomedical engineering, and James Collins, professor in biomedical engineering. The team's findings were reported in the March 4, 2005, issue of Nature Biotechnology.




Related Links:
Boston U. College of Engineering

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Manual Pipetting Aid
Pipette Controllers macro

Latest BioResearch News

Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
29 Mar 2005  |   BioResearch

Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
29 Mar 2005  |   BioResearch

Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
29 Mar 2005  |   BioResearch